BNP Paribas Financial Markets’s NewAmsterdam Pharma NAMS Stock Holding History

BNP Paribas Financial Markets’s Portfolio NAMS Stock Details NAMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.21M	Sell	35,710 -1,740	-5%	-$57.3K	﹤0.01%	3185
2026 Q1	$1.2M	Buy	37,450 +12,316	+49%	+$401K	﹤0.01%	3017
2025 Q4	$882K	Sell	25,134 -2,194	-8%	-$79.8K	﹤0.01%	3199
2025 Q3	$777K	Sell	27,328 -1,949	-7%	-$46.7K	﹤0.01%	3303
2025 Q2	$530K	Buy	29,277 +1,257	+4%	+$22.9K	﹤0.01%	3290
2025 Q1	$574K	Sell	28,020 -7,637	-21%	-$170K	﹤0.01%	3113
2024 Q4	$916K	Buy	+35,657	New	+$757K	﹤0.01%	2885

Other funds holding NAMS

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

DFO

Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

BNP Paribas Financial Markets's NAMS Position: Q2 2026 in Review

BNP Paribas Financial Markets reduced its NewAmsterdam Pharma (NAMS) stake by 4.6% in Q2 2026, selling an estimated $57.3K and leaving 35,710 shares worth $1.21M. The position accounts for ﹤0.01% of the portfolio, ranked #3185.

BNP Paribas Financial Markets first reported a position in NAMS in Q4 2024 and has held it in 7 quarters since. 193 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

BNP Paribas Financial Markets held 35,710 shares of NewAmsterdam Pharma worth $1.21M as of Q2 2026.
BNP Paribas Financial Markets sold 1,740 NewAmsterdam Pharma shares in Q2 2026, an estimated $57.3K.
NewAmsterdam Pharma made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #3185 holding.
BNP Paribas Financial Markets first reported a position in NewAmsterdam Pharma in Q4 2024 and has held it in 7 quarters since.
193 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.